Advertisement

In vitro and in vivo anti-parasitic activity of biogenic antimony sulfide nanoparticles on Leishmania major (MRHO/IR/75/ER)

  • Sina Mohtasebi
  • Mehdi MohebaliEmail author
  • Samira Elikaee
  • Behnaz Akhoundi
  • Abbas Rahimi Foroushani
  • Aref Teimouri
  • Hamed Yarizadeh
Protozoology - Original Paper

Abstract

The aims of this study were to produce biogenic antimony sulfide nanoparticles (NPs) using Serratia marcescens (S. marcescens) and investigate the potential anti-leishmanial effects of these NPs on Leishmania major (L. major) (MRHO/IR/75/ER) in both in vitro and in vivo experiments. Biogenic antimony sulfide NPs were synthesized through intracellular biological methods using S. marcescens. The efficiency of various concentrations of antimony sulfide NPs was assessed using in vitro experiments on amastigotes of L. major at various times post-infection. In vivo experiments were carried out in BALB/c mice inoculated subcutaneously with 2 × 106L. major promastigotes (MHROM/IR/75/ER) and treated with antimony sulfide NPs (70 μg/mL, tropically), meglumine antimoniate (glucantime) as positive control and sterile phosphate-buffered saline (PBS, pH 7.4) as vehicle control. Results of in vitro experiments revealed that the anti-leishmanial activity increased when the antimony sulfide NPs concentration increased. The IC50 (50% inhibitory concentration) of antimony sulfide NPs against amastigotes was calculated as 62.5 μg/mL. In in vivo experiments, the average size of lesions significantly decreased to 8.6 ± 2.7 mm2 in mice inoculated with L. major promastigotes and treated with antimony sulfide NPs, compared with that in the negative control group (P = 0.015). Furthermore, results showed that antimony sulfide NPs significantly decreased the parasite load in the test group, compared with the negative control group (P = 0.001). Various concentrations of antimony sulfide NPs showed a great anti-leishmanial efficiency against L. major (MRHO/IR/75/ER), with the greatest efficiency shown by a concentration of 62.5 μg/mL in in vitro and in vivo experiments.

Keywords

Anti-leishmanial activity Biogenic antimony sulfide Biological synthesis Leishmania major Nanoparticles Serratia marcescens 

Notes

Acknowledgments

We would like to acknowledge all staff from the Department of Pharmaceutical Biotechnology and Pharmaceutical Sciences Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, for their helpful collaborations.

Availability of data and material

The data that support the findings of this study are available on reasonable request to the corresponding author.

Funding information

This study was supported by the Tehran University of Medical Sciences and Health Services (Project No. 94-03-160-30138), Tehran, Iran.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

Animal care and experiments were carried out according to the Guidelines for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and approved by the Ethical Committee of Tehran University of Medical Sciences, Tehran, Iran. The study was approved by the Ethical Committee of Tehran University of Medical Sciences (Approval No. 94-03-160-30138).

Consent for publication

Not applicable (no individual persons data)

References

  1. Abaza SM (2016) Applications of nanomedicine in parasitic diseases. Parasitol United J 9(1):1–6CrossRefGoogle Scholar
  2. Akbari M, Oryan A, Hatam G (2017) Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop 172:86–90CrossRefGoogle Scholar
  3. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho E, Ephros M, Jeronimo S, Magill A (2017) Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 96:24–45CrossRefGoogle Scholar
  4. Arwidsson Z, Allard B (2010) Remediation of metal-contaminated soil by organic metabolites from fungi II—metal redistribution. Water Air Soil Pollut 207:5–18CrossRefGoogle Scholar
  5. Asha Rani P, Low Kah Mun G, Hande MP, Valiyaveettil S (2008) Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3(2):279–290CrossRefGoogle Scholar
  6. Azami SJ, Teimouri A, Keshavarz H, Amani A, Esmaeili F, Hasanpour H, Elikaee S, Salehiniya H, Shojaee S (2018) Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice. Int J Nanomedicine 13:7363–7374CrossRefGoogle Scholar
  7. Bahrami K, Nazari P, Sepehrizadeh Z, Zarea B, Shahverdi AR (2012) Microbial synthesis of antimony sulfide nanoparticles and their characterization. Ann Microbiol 62:1419–1425CrossRefGoogle Scholar
  8. Balaji DS, Basavaraja S, Deshpande R, Mahesh DB, Prabhakar BK, Venkataraman A (2009) Extracellular biosynthesis of functionalized silver nanoparticles by strains of Cladosporium cladosporioides fungus. Colloids Surf B Biointerfaces 68:88–92CrossRefGoogle Scholar
  9. Beheshti N, Soflaei S, Shakibaie M, Yazdi MH, Ghaffarifar F, Dalimi A, Shahverdi AR (2013) Efficacy of biogenic selenium nanoparticles against Leishmania major: in vitro and in vivo studies. J Trace Elem Med Bio 27(3):203–207CrossRefGoogle Scholar
  10. Berman JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684–703CrossRefGoogle Scholar
  11. Bharde A, Rautaray D, Bansal V, Ahmad A, Sarkar I, Yusuf SM, Sanyal M, Sastry M (2006) Extracellular biosynthesis of magnetite using fungi. Small 2:135–141CrossRefGoogle Scholar
  12. Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111–126CrossRefGoogle Scholar
  13. Davidson RN (1998) Practical guide for the treatment of leishmaniasis. Drugs 56(6):1009–1018CrossRefGoogle Scholar
  14. Debbage P (2009) Targeted drugs and nanomedicine: present and future. Curr Pharm Des 15:153–172CrossRefGoogle Scholar
  15. Delavari M, Dalimi A, Ghaffarifar F, Sadraei J (2014) In vitro study on cytotoxic effects of ZnO nanoparticles on promastigote and amastigote forms of Leishmania major (MRHO/IR/75/ER). Iran J Parasitol 9(1):6–13Google Scholar
  16. den Boer M, Argaw D, Jannin J, Alvar J (2011) Leishmaniasis impact and treatment access. Clin Microbiol Infect 17(10):1471–1477CrossRefGoogle Scholar
  17. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27(5):305–318CrossRefGoogle Scholar
  18. Elikaee S, Mohebali M, Rezaei S, Eslami H, Khamesipour A, Keshavarz H, Eshraghian MR (2018) Development of a new live attenuated Leishmania major p27 gene knockout: safety and immunogenicity evaluation in BALB/c mice. Cell Immunol 332:24–31CrossRefGoogle Scholar
  19. El-Khadragy M, Alolayan EM, Metwally DM, El-Din MFS, Alobud SS, Alsultan NI, Alsaif SS, Awad MA, Abdel Moneim AE (2018) Clinical efficacy associated with enhanced antioxidant enzyme activities of silver nanoparticles biosynthesized using Moringa oleifera leaf extract, against cutaneous leishmaniasis in a murine model of Leishmania major. Int J Environ Res Public Health 15(5):E1037CrossRefGoogle Scholar
  20. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D (1999) Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 43:278–282CrossRefGoogle Scholar
  21. Feng R, Wei C, Tu S, Tang S, Wu F (2011) Simultaneous hyperaccumulation of arsenic and antimony in cretan brake fern: evidence of plant uptake and subcellular distributions. Microchem J 97:38–43CrossRefGoogle Scholar
  22. Fletcher RH, Fletcher SW, Wagner EH (1996) Clinical epidemiology: the essentials, 3rd edn. Williams and Wilkins, BaltimoreGoogle Scholar
  23. Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther 12:25–40CrossRefGoogle Scholar
  24. Grimaldi GJ, Tesh RB (1993) Leishmaniases of the New World: current concepts and implications for future research. Clin Microbial Rev 6:230–250CrossRefGoogle Scholar
  25. Gutiérrez V, Seabra AB, Reguera RM, Khandare J, Calderón M (2016) New approaches from nanomedicine for treating leishmaniasis. Chem Soc Rev 45(1):152–168CrossRefGoogle Scholar
  26. Husseiny MI, Abd El-Aziz M, Badr Y, Mahmoud MA (2007) Biosynthesis of gold nanoparticles using Pseudomonas aeruginosa. Spectrochim Acta Part A 67:1003–1006CrossRefGoogle Scholar
  27. Jebali A, Kazemi B (2013) Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis. Toxicol in Vitro 27:1896–1904CrossRefGoogle Scholar
  28. Jha AK, Prasad K, Kulkarni AR (2009a) Synthesis of TiO2 nanoparticles using microorganisms. Colloids Surf B Biointerfaces 71:226–229CrossRefGoogle Scholar
  29. Jha AK, Prasad K, Prasad K (2009b) A green low-cost biosynthesis of Sb2O3 nanoparticles. Biochem Eng J 43:303–306CrossRefGoogle Scholar
  30. Kathiresan K, Manivannan S, Nabeel AM, Dhivya B (2009) Studies on silver nanoparticles synthesized by a marine fungus Penicillum fellutanum isolated from coastal mangrove sediment. Colloids Surf B Biointerfaces 71:133–137CrossRefGoogle Scholar
  31. Khan I, Khan M, Umar MN, Oh DH (2015) Nanobiotechnology and its applications in drug delivery system: a review. IET Nanobiotechnol 9:396–400CrossRefGoogle Scholar
  32. Mandal D, Bolander ME, Mukhopadhyay D, Sarkar G, Mukherjee P (2006) The use of microorganisms for the formation of metal nanoparticles and their application. Appl Microbiol Biotechnol 69:485–492CrossRefGoogle Scholar
  33. Mohebali M, Rezayat M, Gilani K, Sarkar S, Akhoundi B, Esmaeili J et al (2009) Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): an in vitro and in vivo study. Daru 17(4):285–289Google Scholar
  34. Mottram JC, Coombs GH (1985) Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp Parasitol 59:151–160CrossRefGoogle Scholar
  35. Oremland RS, Herbel MJ, Blum JS, Langley S, Beveridge TJ, Ajayan PM, Sutto T, Ellis AV, Curran S (2004) Structural and spectral features of selenium nanospheres produced by Se-respiring bacteria. Appl Environ Microbiol 70:52–60CrossRefGoogle Scholar
  36. Prabhu P, Patravale V, Joshi M (2012) Nanocarriers for effective topical delivery of anti-infectives. Curr Nanosci 8(4):491–503CrossRefGoogle Scholar
  37. Rai M, Gade A, Yadav A (2011) Biogenic nanoparticles: an introduction to what they, how they are synthesized and their applications. In: Rai MK, Duran N (eds) In metal nanoparticles In Microbiology. Springer-Verlag, Berlin Heidelberg, Germany, pp 1–16CrossRefGoogle Scholar
  38. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581–596CrossRefGoogle Scholar
  39. Roberts WL, Berman JD, Rainey PM (1995) In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 39:1234–1239CrossRefGoogle Scholar
  40. Roberts WL, Mcmurray WJ, Rainey PM (1998) Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrob Agents Chemother 42(5):1076–1082CrossRefGoogle Scholar
  41. Rossi-Bergmann B, Pacienza-Lima W, Marcato PD, De Conti R, Durán N (2012) Therapeutic potential of biogenic silver nanoparticles in murine cutaneous leishmaniasis. J Nano Res 20:89–97CrossRefGoogle Scholar
  42. Sereno D, Lemesre JL (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41:972–976CrossRefGoogle Scholar
  43. Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, Lemesre JL (1998) Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 42:3097–3102CrossRefGoogle Scholar
  44. Shakibaei M, Khorramizadeh MR, Faramarzi MA, Sabzevari O, Shahverdi AR (2010) Biosynthesis and recovery of selenium nanoparticles and the effects onmatrixmetalloproteinase-2 expression. Biotechnol Appl Biochem 56:7–15CrossRefGoogle Scholar
  45. Soflaei S, Dalimi A, Ghaffarifar F, Shakibaie M, Shahverdi AR, Shafiepour M (2012) In vitro antiparasitic and apoptotic effects of antimony sulfide nanoparticles on Leishmania infantum. J Parasitol Res 2012:756568CrossRefGoogle Scholar
  46. Teimouri A, Azami SJ, Keshavarz H et al (2018) Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomedicine 13:1341–1351CrossRefGoogle Scholar
  47. Thakkar KN, Mhatre SS, Parikh RY (2010) Biological synthesis of metallic nanoparticles. Nanomed Nanotechnol Biol Med 6:257–262CrossRefGoogle Scholar
  48. Torabi N, Mohebali M, Shahverdi AR, Rezayat SM, Edrissian GH, Esmaeili J et al (2011) Nanogold for the treatment of zoonotic cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): an animal trial with methanol extract of Eucalyptus camaldulensis. JPHS 1:13–16Google Scholar
  49. Vaidyanathan R, Kalishwaralal K, Gopalram S, Gurunathan S (2009) Nanosilver—the burgeoning therapeutic molecule and its green synthesis. Biotechnol Adv 27:924–937CrossRefGoogle Scholar
  50. Veeken H, Ritmeijer K, Seaman J, Davidson R (2000) A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Tropical Med Int Health 5(5):312–317CrossRefGoogle Scholar
  51. Wang JJ, Zeng ZW, Xiao RZ et al (2011) Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine 6:765–774Google Scholar
  52. World Health Organization (2014) Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean RegionGoogle Scholar
  53. Yaghoobi-Ershadi M, Javadian E (1996) Epidemiological study of reservoir hosts in an endemic area of zoonotic cutaneous leishmaniasis in Iran. Bull World Health Organ 74(6):587Google Scholar
  54. Zuccato E, Calamari D, Natangelo M, Fanelli R (2000) Presence of therapeutic drugs in the environment. Lancet 355(9217):1789–1790CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Sina Mohtasebi
    • 1
    • 2
  • Mehdi Mohebali
    • 1
    • 3
    Email author
  • Samira Elikaee
    • 1
  • Behnaz Akhoundi
    • 1
  • Abbas Rahimi Foroushani
    • 4
  • Aref Teimouri
    • 1
  • Hamed Yarizadeh
    • 1
  1. 1.Department of Medical Parasitology and Mycology, School of Public HealthTehran University of Medical SciencesTehranIran
  2. 2.Students Scientific Research CenterTehran University of Medical SciencesTehranIran
  3. 3.Research Center for Endemic ParasitesTehran University of Medical SciencesTehranIran
  4. 4.Department of Epidemiology and Biostatistics, School of Public HealthTehran University of Medical SciencesTehranIran

Personalised recommendations